13F filerCIK 1061768 ↗
Baupost Group
You are looking at Q3 2018. See the latest, Q3 2026 →
Reported value
$13.06B
+14% on the quarter before
Positions
38
6 new, 1 sold out
Top 10
72.0%
of the value
Est. gain
−$118.7M
on stocks held all quarter
Est. return
−1.2%
on those stocks since Q2 2018
Positions as of Sep 30, 2018, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2018. Striped tiles are options.
Largest buys
Since Q2 2018, sized at quarter-end prices.
- Pg&E Corp~$666.2MAdded, 1.7% → 6.7% of the portfolio+14,479,790 shares
- Twenty First Centy Fox Inc~$583.1MAdded, 17.1% → 18.5% of the portfolio+12,585,338 shares
- Liberty Global Plc~$303.3MNew, 0.0% → 2.3% of the portfolio+10,768,870 shares
- Altaba Inc~$191.5MNew, 0.0% → 1.5% of the portfolio+2,810,775 shares
- Twenty First Centy Fox Inc~$170.2MAdded, 5.9% → 6.1% of the portfolio+3,714,662 shares
- Liberty Global Plc~$143.4MNew, 0.0% → 1.1% of the portfolio+4,957,205 shares
- Tribune Media Co~$115.3MAdded, 1.0% → 1.8% of the portfolio+3,000,000 shares
- Ypf Sociedad Anonima~$92.7MNew, 0.0% → 0.7% of the portfolio+6,000,000 shares
- Amerisourcebergen Corp~$80.9MAdded, 1.4% → 1.9% of the portfolio+877,491 shares
- Mckesson Corp~$72.7MAdded, 1.9% → 2.2% of the portfolio+548,000 shares
Largest sells
Since Q2 2018, sized at quarter-end prices.
- Synchrony Finl~$402.9MCut, 8.5% → 3.9% of the portfolio−12,962,101 shares
- AT&T~$304.4MSold out, 2.7% → 0.0% of the portfolio−9,480,700 shares
- Amc Entmt Hldgs Inc~$46.5MCut, 0.7% → 0.4% of the portfolio−2,268,700 shares
- Cardinal Health Inc~$19.5MCut, 2.2% → 2.0% of the portfolio−361,515 shares
- Veritiv Corp~$9.5MCut, 1.3% → 1.0% of the portfolio−259,946 shares
Holdings
As of Sep 30, 2018; changes in shares since Jun 30, 2018.
| Holding | Value | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Twenty First Centy Fox IncCL A · shares +32% · price −6.8% | 18.5% | $2.41B | −$132.4M | ||||||
| Cheniere Energy IncCOM NEW · shares 0% · price +6.6% | 7.6% | $986.5M | +$61.0M | ||||||
| Allergan PlcSHS · shares 0% · price +14.3% | 7.2% | $942.9M | +$117.6M | ||||||
| Viasat IncCOM · shares 0% · price −2.7% | 6.7% | $878.2M | −$24.3M | ||||||
| Pg&E CorpCOM · shares +322% · price +8.1% | 6.7% | $873.3M | +$15.5M | ||||||
| QorvoCOM · shares 0% · price −4.1% | 6.5% | $845.8M | −$36.1M | ||||||
| Twenty First Centy Fox IncCL B · shares +27% · price −7.0% | 6.1% | $793.6M | −$46.9M | ||||||
| Pioneer Nat Res CoCOM · shares 0% · price −8.0% | 5.3% | $696.8M | −$60.2M | ||||||
| Synchrony FinlCOM · shares −44% · price −6.9% | 3.9% | $507.6M | −$37.6M | ||||||
| Antero Res CorpCOM · shares 0% · price −17.0% | 3.6% | $470.9M | −$96.8M | ||||||
| TeslaNOTE 2.375% 3/1 · shares +20% · price −16.0% | 2.4% | $308.6M | — | ||||||
| Theravance Biopharma IncCOM · shares 0% · price +44.0% | 2.3% | $304.1M | +$93.0M | ||||||
| Liberty Global PlcSHS CL C · shares New | 2.3% | $303.3M | — | ||||||
| Colony Cap Inc NewCL A COM · shares 0% · price −2.4% | 2.3% | $302.6M | −$7.5M | ||||||
| Mckesson CorpCOM · shares +34% · price −0.6% | 2.2% | $288.6M | −$1.2M | ||||||
| Atara Biotherapeutics IncCOM · shares 0% · price +12.5% | 2.0% | $258.6M | +$28.8M | ||||||
| Cardinal Health IncCOM · shares −7.1% · price +10.6% | 2.0% | $255.9M | +$24.5M | ||||||
| Amerisourcebergen CorpCOM · shares +47% · price +8.2% | 1.9% | $253.7M | +$13.0M | ||||||
| Tribune Media CoCL A · shares +100% · price +0.4% | 1.8% | $230.4M | +$478,947 | ||||||
| Altaba IncCOM · shares New | 1.5% | $191.5M | — | ||||||
| Liberty Global PlcSHS CL A · shares New | 1.1% | $143.4M | — | ||||||
| Veritiv CorpCOM · shares −6.8% · price −8.7% | 0.99% | $129.7M | −$12.3M | ||||||
| Ypf Sociedad AnonimaSPON ADR CL D · shares New | 0.71% | $92.7M | — | ||||||
| Keryx Biopharmaceuticals IncCOM · shares 0% · price −9.6% | 0.67% | $87.7M | −$9.3M | ||||||
| Sinclair Broadcast Group IncCL A · shares +17% · price −11.8% | 0.65% | $85.0M | −$9.8M | ||||||
| Total 38 positions | 100% | $13.06B | −$118.7M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2018 to Q3 2018: 30 stocks held throughout, down $118.7M (−1.2%).
- Allergan Plc+$117.6M+14%
- Theravance Biopharma Inc+$93.0M+44%
- Cheniere Energy Inc+$61.0M+7%
- Atara Biotherapeutics Inc+$28.8M+13%
- Cardinal Health Inc+$24.5M+11%
- Synchrony Finl−$37.6M−7%
- Twenty First Centy Fox Inc−$46.9M−7%
- Pioneer Nat Res Co−$60.2M−8%
- Antero Res Corp−$96.8M−17%
- Twenty First Centy Fox Inc−$132.4M−7%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | $5.05B−7% | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | $5.42B+6% | SEC ↗ |
| Q1 2026 | May 14, 2026 | $5.12B−3% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $5.28B+10% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $4.79B+16% | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | $4.13B+18% | SEC ↗ |
| Q1 2025 | May 14, 2025 | $3.50B+2% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $3.43B−2% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $3.52B−3% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $3.63B−0% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $3.65B−20% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $4.59B−12% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $5.21B−7% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $5.61B−4% | SEC ↗ |
| Q1 2023 | May 12, 2023 | $5.85B−5% | SEC ↗ |
| Q4 2022 | Feb 13, 2023 | $6.13B+6% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $5.79B−14% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $6.77B−27% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $9.30B−8% | SEC ↗ |
| Q4 2021 | Feb 11, 2022 | $10.13B−7% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $10.88B−12% | SEC ↗ |
| Q2 2021 | Aug 13, 2021 | $12.33B−2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $12.56B+16% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $10.84B+17% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $9.25B+15% | SEC ↗ |
| Q2 2020 | Aug 13, 2020 | $8.01B+18% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $6.77B−25% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $9.06B+3% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $8.83B−20% | SEC ↗ |
| Q2 2019 | Aug 13, 2019 | $11.05B−7% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $11.90B+3% | SEC ↗ |
| Q4 2018 | Feb 13, 2019 | $11.52B−12% | SEC ↗ |
| Q3 2018 | Nov 15, 2018 (amended) | $13.06B+14% | SEC ↗ |
| Q2 2018 | Aug 13, 2018 | $11.44B+10% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $10.37B+3% | SEC ↗ |
| Q4 2017 | Feb 13, 2018 | $10.11B+26% | SEC ↗ |
| Q3 2017 | Nov 13, 2017 | $8.02B−8% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $8.75B+3% | SEC ↗ |
| Q1 2017 | May 25, 2017 (amended) | $8.49B+11% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $7.67B+9% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $7.04B−4% | SEC ↗ |
| Q2 2016 | Aug 12, 2016 | $7.37B+6% | SEC ↗ |
| Q1 2016 | May 13, 2016 | $6.92B | SEC ↗ |